EDITORIAL GOVERNANCE & MEDICAL REVIEW
-
✓
Content Author: Ms. Hannah Matthews (B.Sc. - Biochemistry)
-
✓
Medically Reviewed By: Dr. N Kumar, MD, DM (Neurology), Member of the International Society for Stem Cell Research (ISSCR).
-
✓
State Medical Council Registration No.: Medical Registration Verified | Member, Indian Academy of Neurology
-
✓
Expert Scientific Reviewer: Dr. Harinath P, PhD (Stem Cell Biology & Regenerative Immunology)
-
✓
Clinical Governance Protocol:
SOP-AVN-03(Investigational Cellular Protocol)
Condition Context & Investigational Scope
Clinical classification, underlying pathophysiology, and biological cellular rationale in India
Clinical Classification & Regulatory Status:
Core decompression augmented with autologous Bone Marrow Aspirate Concentrate (BMAC) is an established joint-preservation orthobiologic procedure for pre-collapse disease. The use of cultured, ex vivo expanded, or allogeneic mesenchymal stem cells is strictly investigational under Indian regulatory mandates.
Pathophysiology & Disease Context:
Avascular Necrosis (AVN / Osteonecrosis), most commonly affecting the femoral head, talus, or humeral head, results from disrupted microvascular blood supply leading to osteocyte death, subchondral microfractures, and progressive articular surface collapse.
Biological Rationale & Paracrine Action:
Percutaneous core decompression reduces elevated intraosseous pressure, while concentrated autologous progenitor cells and angiogenic growth factors (VEGF, FGF, BMPs) stimulate neovascularization and new trabecular bone remodeling in the ischemic necrotic zone.
Candidate Eligibility & Diagnostic Pre-Screening
Comprehensive inclusion markers, mandatory diagnostics, and safety exclusion parameters
Target Patient Profile:
Patients with documented pre-collapse avascular necrosis (Ficat-Arlet Stages I–II or ARCO Stages 1–2 / early 3A) seeking hip or joint preservation before mechanical flattening occurs.
Mandatory Pre-Procedure Diagnostics:
High-resolution 3T MRI of the involved joint (< 2 months old), standing weight-bearing AP and frog-leg lateral radiographs (measuring necrotic angle and sphericity), inflammatory markers (ESR, CRP), and coagulopathy screen.
Strict Safety Exclusion Parameters:
Advanced stage disease with subchondral collapse, crescent sign with articular depression, or secondary osteoarthritis (Ficat-Arlet Stages III–IV / ARCO Stage 4) requiring total hip arthroplasty (THA); active bone infection (osteomyelitis); or severe uncontrolled medical comorbidities.
Triage Protocol & Multi-Specialty Clearance:
Pre-travel multi-disciplinary medical board evaluation and baseline scan review prior to issuing medical visa invitation clearance.
Potential Functional Goals & Documented Risks
Reported supportive clinical goals alongside complete procedural and biological risk transparency
Reported Functional Goals (Supportive & Variable):
- Pain Relief: Substantial drop in groin and weight-bearing pain scores (VAS) due to intraosseous decompression.
- Delay or Prevention of Joint Collapse: Preservation of native femoral head sphericity and structural integrity on serial follow-up imaging.
- Improved Joint Mobility: Enhanced functional range of motion and significant gains on the Modified Harris Hip Score (mHHS).
- Delayed Need for Arthroplasty: Extending native joint survivorship, particularly valuable for young and active patients.
Documented Procedural Risks & Limits:
- Post-operative donor-site pain (iliac crest) or transient hip soreness lasting 48–72 hours.
- Risk of iatrogenic subtrochanteric fracture if post-operative protected weight-bearing guidelines are breached.
- No Guaranteed Reversal: Biologic therapy cannot restore a collapsed femoral head, regenerate fully dead cortical bone, or guarantee non-progression if underlying risk factors (e.g., ongoing high-dose steroid therapy, heavy alcohol use) continue.
Why Undergo Treatment at Our Medical Center in India?
World-class tertiary healthcare infrastructure, cGMP certified cleanrooms, and compassionate patient-centered care
Accredited Infrastructure
Procedures performed in tertiary orthopedic hospitals accredited by NABH and JCI.
Fluoroscopic Precision
100% of core decompression and cell deposition procedures executed under continuous digital fluoroscopy to ensure precise delivery into the necrotic epicenter.
Joint Preservation Surgeons
Led by fellowship-trained orthopedic surgeons experienced in pre-collapse biological salvaging techniques.
Ethical Standards
Fully compliant with National Medical Commission (NMC) guidelines; patients with established structural collapse are directed toward total joint replacement rather than non-indicated biologics.
Treatment Costs & Package Inclusions
Transparent international pricing with comprehensive hospital, procedural, and travel inclusions
(comprehensive inpatient package covering targeted cellular therapy, hospital stays, and follow-up).
(Administered under strict cGMP cleanroom standards and multidisciplinary physician oversight).
| Country / Region | Typical Package Range | Waiting Period | Clinical Accreditation |
|---|---|---|---|
| India (Our Partner Centers) | Starting from $4,000 USD | 1 – 2 Weeks | JCI / NABH Accredited |
| United States | $28,000 – $55,000 USD | 3 – 6 Months | Clinical Trial Gated |
| Germany & Switzerland | $25,000 – $48,000 USD | 2 – 4 Months | Private Specialty Only |
| Panama / Mexico | $18,000 – $35,000 USD | 2 – 4 Weeks | Variable Regional |
Dedicated Support for International Patients & Families
End-to-end medical concierge care ensuring a safe, stress-free international treatment journey
Pre-Arrival Video Consultation
Remote telemedicine conference with senior orthopedic surgeons to examine MRI cuts, measure necrotic volume, and confirm candidacy.
Government Medical Visa
Fast-track assistance with official Government of India Medical Visa (MED) and Medical Attendant (MED-X) invitation letters.
Dedicated Case Liaison
Single multilingual point of contact coordinating airport transfers, hospital admission, assistive devices, and medical documentation.
Remote Post-Operative Monitoring
Scheduled telemedicine check-ins at Months 1, 3, 6, and 12, coordinating weight-bearing progression and follow-up MRI reviews with your local physician.
Travel, Accommodation & Local Logistics
Planning your medical journey to New Delhi, Mumbai, or Bangalore with complete peace of mind
Accessible Airport Transfers
Private, air-conditioned vehicle pick-up and drop-off accommodating wheelchairs, crutches, and mobility aids.
Accessible Partner Accommodations
Partner 4-star and 5-star serviced apartments located within 10 minutes of the hospital, featuring step-free access, wide doorways, walk-in showers, and elevator facilities.
Patient Amenities
High-protein, bone-supportive dietary meal options, local SIM card registration, wheelchair loaners, and 24/7 nursing availability.
Clinical Protocol & In-Hospital Schedule
Structured clinical workflow during your stay in India (Stay Duration: 3 to 4 days structured inpatient/short-stay orthopedic pathway.):
Arrival, Admission & Baseline Diagnostics
Airport reception, hospital check-in, primary physician review, comprehensive blood panels, vital organ assessment, and baseline imaging scans.
Pre-Procedure Preparation & Multi-Specialty Clearance
Review of diagnostic profiles by the clinical committee, premedication, and certified cleanroom preparation of cellular biologics.
Targeted Cellular Administration
Delivery of clinical-grade cellular biologics under strict aseptic conditions in an advanced surgical/interventional procedure suite.
Post-Procedure Observation, Supportive Care & Discharge
Vital sign stability monitoring, supportive therapy, discharge counseling, and fit-to-fly clearance certification.
Clinical Safety Profile & Post-Treatment Monitoring
Rigorous clinical governance, low adverse event rates, and structured long-term remote follow-up
Anticipated Transient Responses
- Mild transient low-grade fever resolving within 12 to 24 hours.
- Mild localized injection-site soreness or temporary tenderness.
- Transient procedural fatigue responsive to oral hydration and rest.
Quality & Cleanroom Safeguards
- Certified cGMP cleanroom facilities with ISO-Class 5 / Class 10,000 air handling.
- Flow cytometry viability testing (>90% cell viability confirmed).
- Rigorous sterility screening for endotoxins, mycoplasma, and viral pathogens.
Structured 12-Month Remote Follow-Up Care
Following discharge, our medical team conducts scheduled teleconsultations at 1, 3, 6, and 12 months to review functional progress, track laboratory biomarkers, and coordinate directly with your local physician.
Frequently Asked Questions
Evidence-based answers to key clinical, safety, cost, and travel inquiries regarding Avascular Necrosis (AVN)
Peer-Reviewed Clinical Trial References & Registry Citations
Published scientific trials, systematic reviews, and official registry citations validating cellular safety and therapeutic mechanisms
Landmark Long-Term Prospective Clinical Trial on BMAC Core Decompression in Femoral Head AVN
Hernigou, P., Beaujean, F. (2002). Treatment of osteonecrosis with autologous bone marrow grafting. Clinical Orthopaedics and Related Research, (405), 14–23. / Hernigou, P., Poignard, A., Zilber, S., & Rouard, H. (2009). Cell therapy of hip osteonecrosis with autologous bone marrow concentrated cells: long-term results and factors influencing the outcome. International Orthopaedics, 33(4), 913–921.
Randomized Controlled Trial: Core Decompression with BMAC vs. Core Decompression Alone
Sen, R. K., Tripathy, S. K., Aggarwal, S., Marwaha, N., Sharma, R. R., & Khandelwal, N. (2012). Early results of core decompression and autologous bone marrow mononuclear cells instillation in femoral head osteonecrosis: a randomized control study. Journal of Arthroplasty, 27(5), 679–686.
Comparative Trial: Bone Marrow Concentrate Grafting vs. Vascularized Bone Grafting
Rastogi, S., Sankineani, S. R., Nag, H. L., Mohanty, S., Shivanand, G., Marimuthu, K., & Kumar, R. (2013). Intralesional autologous mesenchymal stem cells in early stages of femoral head osteonecrosis. Indian Journal of Orthopaedics, 47(3), 283–289.
Systematic Review & Meta-Analysis of Mesenchymal Stem Cell Augmentation in AVN
Piuzzi, N. S., Chahla, J., Schrock, J. B., LaPrade, R. F., Pascual-Garrido, C., Mont, M. A., & Muschler, G. F. (2017). Evidence for the Use of Cell Therapy in the Treatment of Osteonecrosis of the Femoral Head: A Systematic Review of the Literature. The Journal of Arthroplasty, 32(5), 1698–1708.
Statutory Notice & Mandatory Regulatory Disclosure:
In compliance with the National Guidelines for Stem Cell Research jointly formulated by the Indian Council of Medical Research (ICMR) and Department of Biotechnology (DBT), autologous point-of-care orthobiologics (such as BMAC used during core decompression) must follow minimal-manipulation principles. The administration of ex vivo cultured, expanded, or allogeneic stem cells for avascular necrosis is classified as strictly investigational and experimental. Cellular augmentation is designed to preserve early-stage joints and cannot rebuild an already collapsed femoral head or substitute for total hip arthroplasty in advanced stages. Patients must strictly adhere to prescribed protected weight-bearing timelines (typically 4–6 weeks) to prevent post-procedural structural failure.
In compliance with the National Guidelines for Stem Cell Research jointly formulated by ICMR and DBT, and directives from NMC, cellular therapies described on this website are investigational. Patients should never alter or stop prescribed baseline medications without consulting their primary physician.